Coherus BioSciences Inc (NAS:CHRS)
$ 0.73 0.06 (8.96%) Market Cap: 84.11 Mil Enterprise Value: 187.54 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 39/100

Coherus BioSciences Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 03:50PM GMT
Release Date Price: $17.58 (-3.30%)
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning, everybody. I'm Chris Schott from JPMorgan. And it's my pleasure to be introducing Coherus today at the JPMorgan Healthcare Conference.

From the company, we have Denny Lanfear, the company's President and CEO. Looking forward to Denny's comments. But before that, I did want to remind everybody, this will be a 40-minute session. (Operator Instructions)

So with that, I'll turn it over to Denny for the presentation.

Dennis M. Lanfear
Coherus BioSciences, Inc. - Chairman, President & CEO

Thank you, Chris, and thank you once again for inviting Coherus to present at the annual JPMorgan conference. It's a pleasure to be here.

Let me first, of course, apprise you of the forward-looking statements on Page 2 and direct you to the company's SEC filings with respect to each of the company's products, CHS-1420, our Humira biosimilar, as well as UDENYCA, our product, and so on.

Now on Slide 3, I'll just summarize for you our agenda

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot